Literature DB >> 19189187

Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months.

Salvatore Pucciarelli1, Giuseppe Gagliardi, Isacco Maretto, Sara Lonardi, Maria Luisa Friso, Emanuele Urso, Paola Toppan, Donato Nitti.   

Abstract

BACKGROUND: This study sought to evaluate the long-term outcome and complications, and occurrence of second malignancy after preoperative chemoradiotherapy (pCRT) for rectal cancer.
METHODS: One hundred twenty-three consecutive patients (78 men, 45 women) with locally advanced mid-low rectal cancer underwent pCRT between 1994 and 2002. Patients were followed up by one surgeon with a standard protocol, and data were prospectively recorded in a dedicated database. No patient was lost to follow-up. Complications were defined as late if they occurred >6 months after surgery. Overall and disease-free survival were calculated by the Kaplan-Meier method.
RESULTS: Of 123 patients, 111 underwent an R0 procedure. The rate of pathologic complete response was 16% (n = 20 patients). At a median follow-up of 95 (range, 56-160) months, 50 late complications occurred in 41 patients, 21 of whom required surgery. In seven cases, the complications were clearly CRT related and were significantly associated with the total dose of radiation delivered (P < .05). The estimated 5- and 10-year overall survival was 76% and 67%, respectively. The estimated 5- and 10-year disease-free survival was 83% and 82%, respectively. In 18 of 19 patients who experienced recurrence (local, n = 3; distant, n = 16), it occurred within 48 months from surgery. The most frequent site of metastasis as first site of recurrence was the lung (9 of 19). The most frequent second primary malignancy was lung cancer (3 of 8).
CONCLUSIONS: Despite satisfactory oncological outcome, late morbidity after pCRT is relevant and related to the radiotherapy dose used. Most recurrences and second malignancies were located in the lung.

Entities:  

Mesh:

Year:  2009        PMID: 19189187     DOI: 10.1245/s10434-009-0335-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  What factors influence 10-year survival after curative resection of a colorectal carcinoma?

Authors:  Torsten Ueberrueck; Christine Wurst; Falk Rauchfuß; Thomas Knösel; Utz Settmacher; Annelore Altendorf-Hofmann
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

2.  Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.

Authors:  Naruhiko Ikoma; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; Cathy Eng; Prajnan Das; Scott Kopetz; Craig Messick; John M Skibber; George J Chang
Journal:  J Clin Oncol       Date:  2017-06-28       Impact factor: 44.544

3.  Clinical outcome of patients with complete pathological response to neoadjuvant chemoradiotherapy for locally advanced rectal cancers: the Indian scenario.

Authors:  Snita Sinukumar; Prachi Patil; Reena Engineer; Ashwin Desouza; Avanish Saklani
Journal:  Gastroenterol Res Pract       Date:  2014-12-28       Impact factor: 2.260

4.  N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.

Authors:  Xiao Yang; Fan Zhu; Chaoran Yu; Jiaoyang Lu; Luyang Zhang; Yanfeng Lv; Jing Sun; Minhua Zheng
Journal:  Oncotarget       Date:  2017-07-18

5.  Physical activity levels in locally advanced rectal cancer patients following neoadjuvant chemoradiotherapy and an exercise training programme before surgery: a pilot study.

Authors:  Lisa Loughney; Malcolm A West; Borislav D Dimitrov; Graham J Kemp; Michael Pw Grocott; Sandy Jack
Journal:  Perioper Med (Lond)       Date:  2017-02-16

6.  Accuracy of colorectal cancer ICD-9-CM codes in Italian administrative healthcare databases: a cross-sectional diagnostic study.

Authors:  Francesco Cozzolino; Ettore Bidoli; Iosief Abraha; Mario Fusco; Gianni Giovannini; Paola Casucci; Massimiliano Orso; Annalisa Granata; Marcello De Giorgi; Paolo Collarile; Valerio Ciullo; Maria Francesca Vitale; Roberto Cirocchi; Walter Orlandi; Diego Serraino; Alessandro Montedori
Journal:  BMJ Open       Date:  2018-07-05       Impact factor: 2.692

7.  Prognosis and risk factors for the development of pulmonary metastases after preoperative chemoradiotherapy and radical resection in patients with locally advanced rectal cancer.

Authors:  Weihao Li; Jianhong Peng; Cong Li; Lifang Yuan; Wenhua Fan; Zhizhong Pan; Xiaojun Wu; Junzhong Lin
Journal:  Ann Transl Med       Date:  2020-02

8.  The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial.

Authors:  Lisa Loughney; Malcolm A West; Graham J Kemp; Harry B Rossiter; Shaunna M Burke; Trevor Cox; Christopher P Barben; Michael G Mythen; Peter Calverley; Daniel H Palmer; Michael P W Grocott; Sandy Jack
Journal:  Trials       Date:  2016-01-13       Impact factor: 2.279

9.  Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management.

Authors:  Leila T Tchelebi; Paul B Romesser; Sebastian Feuerlein; Sarah Hoffe; Kujtim Latifi; Seth Felder; Michael D Chuong
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

10.  The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial).

Authors:  Lisa Loughney; Malcolm A West; Michael P W Grocott; Sandy Jack; Helen Moyses; Andrew Bates; Graham J Kemp; Lesley Hawkins; Judit Varkonyi-Sepp; Shaunna Burke; Christopher P Barben; Peter M Calverley; Trevor Cox; Daniel H Palmer; Michael G Mythen
Journal:  Perioper Med (Lond)       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.